A Phase II Study Evaluating the Safety and Efficacy of Sunitinib Malate in Combination With Weekly Paclitaxel Followed by Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF as Neoadjuvant Chemotherapy for Locally Advanced or Inflammatory Breast Cancer

MLA

Ursa Brown-Glaberman, et al. “A Phase II Study Evaluating the Safety and Efficacy of Sunitinib Malate in Combination With Weekly Paclitaxel Followed by Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF as Neoadjuvant Chemotherapy for Locally Advanced or Inflammatory Breast Cancer.” Clinical Breast Cancer, vol. 22, Jan. 2022, pp. 32–42. EBSCOhost, https://doi.org/10.1016/j.clbc.2021.05.009.

APA

Ursa Brown-Glaberman, Hannah M. Linden, Lynn Symonds, Jennifer M. Specht, Eve T. Rodler, Isaac C. Jenkins, Xiaoyu Chai, Georgiana K. Ellis, Pavani Chalasani, Jinny Riedel, Brenda F. Kurland, Julie Gralow, Alison Stopeck, Qian Wu, & Vijayakrishna V K Gadi. (2022). A Phase II Study Evaluating the Safety and Efficacy of Sunitinib Malate in Combination With Weekly Paclitaxel Followed by Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF as Neoadjuvant Chemotherapy for Locally Advanced or Inflammatory Breast Cancer. Clinical Breast Cancer, 22, 32–42. https://doi.org/10.1016/j.clbc.2021.05.009

Chicago

Ursa Brown-Glaberman, Hannah M. Linden, Lynn Symonds, Jennifer M. Specht, Eve T. Rodler, Isaac C. Jenkins, Xiaoyu Chai, et al. 2022. “A Phase II Study Evaluating the Safety and Efficacy of Sunitinib Malate in Combination With Weekly Paclitaxel Followed by Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF as Neoadjuvant Chemotherapy for Locally Advanced or Inflammatory Breast Cancer.” Clinical Breast Cancer 22 (January): 32–42. doi:10.1016/j.clbc.2021.05.009.